FundamentalVR Offers Teleflex a Scalable Training Platform to Accelerate the Effective Use of the UroLift® 2 System for Treatment of Enlarged Prostate
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced a new agreement with FundamentalVR, a world leader in virtual reality (VR) integration for medical simulation. The agreement will provide Teleflex with a VR training platform to accelerate the effective use of the company’s UroLift® 2 System, an innovative technology for treatment of benign prostatic hyperplasia (BPH), commonly known as enlarged prostate. The VR training platform integrates tactile feedback and a digital representation of the UroLift® 2 System to provide urologists with a “hands-on” VR experience that can accelerate their learning.
By leveraging the capabilities of FundamentalVR’s Fundamental Surgery platform, Teleflex aims to increase access and standardization of clinical training of the UroLift® 2 System in the United States and around the world, including Japan, where the UroLift® 2 System was recently approved for use. The customized solution from FundamentalVR will enable urologists globally to practice the procedure remotely in a virtual environment.
Teleflex showcased the Fundamental Surgery platform at the company’s UroLift® System booth at the 2022 American Urological Association (AUA) meeting in New Orleans. The platform is officially launching and becoming available in August 2022.
“We are delighted to offer our customers this leading VR platform for surgical and procedural education which offers advanced, realistic graphics to help demonstrate the ease of use of the UroLift® 2 System in a variety of prostate anatomies,” said Kevin Hardage, President and General Manager of Teleflex Interventional Urology. “FundamentalVR’s Fundamental Surgery platform is versatile and scalable, making them an ideal supplier to meet our customers’ needs for training for the UroLift® 2 System around the world.”
Chris Scattergood, co-founder at FundamentalVR said, “We are delighted that Teleflex, a market leader in urology, has chosen FundamentalVR as their partner for their future vision. Integrating Extended Reality education solutions can have a positive impact on surgeons and patients.”
About the UroLift® System
The UroLift® System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 45 years or older (50 years outside U.S.). The UroLift® permanent implants, which can be delivered during an outpatient procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift® System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.1 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*2-4 Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.5 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift® System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. More than 350,000 men have been treated with the UroLift® System in select markets worldwide.6 Learn more at UroLift.com. Rx only.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®, QuikClot®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.
About FundamentalVR
FundamentalVR delivers immersive and high fidelity multi-user simulations underpinned with HapticVRTM interactions. This enables medical devices and procedures to drive consistency and compliance across their training programs, provided on their multimodal Fundamental Surgery platform. The platform allows for full rehearsal of medical and surgical procedures in a safe and compliant virtual space, providing deep data insight into competency and skills development, accelerating safe adoption across the board, and is the only platform accredited by leading global education institutions. Their unlimited multi-user capabilities and mixed modalities all work individually or together for each business case, accelerating the time in which products and procedures can be brought to market and improve patient outcomes.
Contacts:
Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
John Hsu, CFA
Vice President, Investor Relations
Investors.teleflex.com
610-948-2836
Media:
Nicole Osmer
nicole@healthandcommerce.com
650.454.0504
*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.
References:
1. Rukstalis, Prostate Cancer and Prostatic Dis 2018
2. Roehrborn, Can J Urol 2017
3. AUA BPH Guidelines 2003, 2021
4. McVary, J Sex Med 2016
5. Roehrborn, J Urology 2013
6. Management estimate based on product sales as of April 2022. Data on file Teleflex Interventional Urology.
HapticVR is a trademark or registered trademark of FundamentalVR or its affiliates.
Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck, are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.
© 2022 Teleflex Incorporated. All rights reserved. MAC02549-01 Rev A
